5MC Stock Chart & Stats
€1.45
€0.16(5.13%)
At close: 4:00 PM EST
€1.45
€0.16(5.13%)
Day’s Range― - ―
52-Week Range€0.03 - €3.00
Previous CloseN/A
Volume0.00
Average Volume (3M)4.73K
Market Cap
€67.96M
Enterprise Value€126.92
Total Cash (Recent Filing)€6.69M
Total Debt (Recent Filing)€38.00K
Price to Earnings (P/E)―
Beta2.97
Next Earnings
Aug 17, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding106,464,485
10 Day Avg. Volume0
30 Day Avg. Volume4,732
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentPromising efficacy data point to market potential of DNK-01 in approximately 25%-50% of 2L patients.
Financial StabilityThe company reported approximately $47M in cash and cash equivalents at the end of 4Q24, which is believed to be sufficient to fund operations.
Bears Say
Pipeline DevelopmentUncertainties regarding the company's pipeline development and lack of meaningful catalysts contribute to the Neutral rating on LPTX.
Strategic PartnershipsThe company still needs to identify a partner to run the registrational Phase 3 study.
Cypherpunk Technologies News
5MC FAQ
What was Cypherpunk Technologies Inc.’s price range in the past 12 months?
Cypherpunk Technologies Inc. lowest stock price was €0.03 and its highest was €3.00 in the past 12 months.
What is Cypherpunk Technologies Inc.’s market cap?
Cypherpunk Technologies Inc.’s market cap is €67.96M.
When is Cypherpunk Technologies Inc.’s upcoming earnings report date?
Cypherpunk Technologies Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 32 days.
How were Cypherpunk Technologies Inc.’s earnings last quarter?
Cypherpunk Technologies Inc. released its earnings results on May 14, 2026. The company reported -€0.401 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Cypherpunk Technologies Inc. overvalued?
According to Wall Street analysts Cypherpunk Technologies Inc.’s price is currently Overvalued.
Does Cypherpunk Technologies Inc. pay dividends?
Cypherpunk Technologies Inc. does not currently pay dividends.
What is Cypherpunk Technologies Inc.’s EPS estimate?
Cypherpunk Technologies Inc.’s EPS estimate is -0.03.
How many shares outstanding does Cypherpunk Technologies Inc. have?
Cypherpunk Technologies Inc. has 106,464,485 shares outstanding.
What happened to Cypherpunk Technologies Inc.’s price movement after its last earnings report?
Cypherpunk Technologies Inc. reported an EPS of -€0.401 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.229%.
Which hedge fund is a major shareholder of Cypherpunk Technologies Inc.?
Currently, no hedge funds are holding shares in DE:5MC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cypherpunk Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
125.14%
12-Months-Change
Fundamentals
Return on Equity
-46.86%
Trailing 12-Months
Asset Growth
150.52%
Trailing 12-Months
Company Description
Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
Technical Analysis
Imunon
―
XTL Biopharmaceuticals Sponsored ADR
―
Carisma Therapeutics
―
MetaVia
―
Allarity Therapeutics
―